Raj Makkar, MD, Cedars-Sinai, explains the late-breaking data from the Align-AR trial on the first 500 patients treated for aortic regurgitation using the Jena Valve TAVR device.

Currently there are no FDA cleared echocardiography contrast agents commercially available for use on the right side of the heart to detect shunts, but a new agent that promises to improve workflow and imaging is about to enter a U.S. trial. 

ACC President Christopher Kramer, MD, testified before a Congressional subcommittee to ask for federal funding to support a new law aimed at reducing sudden cardiac arrest deaths, and to support NIH research.

ACC Immediate Past President Cathie Biga spoke to Cardiovascular Business about some of the challenges healthcare faces in the wake of mass layoffs and significant funding cuts put in place by the Trump administration.

He is accused of claiming to be a cardiologist from London and performing heart surgeries at a hospital in India.

CardioVia's ViaOne technology includes a blunt-tip needle that remains concealed to help interventional cardiologists and electrophysiologists treat cardiac arrhythmias with a reduced risk of perforation or any other complications. 

Richard Kovacs, MD, detailed some the most important late-breaking cardiology pharmacology trials presented at ACC.25.

COVID-19 may help explain the increased rates of cardiac and noncardiac mortality among TAVR patients, but there are several other factors to consider as well. Researchers explored nearly 11 years of STS/ACC registry data to learn more.

The authors of the survey report note that AI tools mentioned by respondents run the gamut from automated appointment reminders to dynamic “care gap” messaging. 

Despite the improvement, physicians remain at greater risk for such workplace fatigue when compared to other professions, the AMA reports. 

President Trump announced that most of his "reciprocal" tariffs have been halted. However, he raised those on Chinese goods to 125%.  

A new study focuses on the role oxalic acid may play in the body’s ability to eliminate gadolinium after an MRI study.

Researchers at Oregon State University are working on developing a way to make contrast agents more targeted. 

Paul Rodrigue, MD, went missing last week and was last seen on Saturday, March 29, in the Mid-City area.